Zomedica (NYSEAMERICAN:ZOM) Shares Down 2.2% – Should You Sell?

Shares of Zomedica Corp. (NYSEAMERICAN:ZOM) traded down 2.2% on Thursday . The company traded as low as $0.13 and last traded at $0.14. 8,794,663 shares traded hands during mid-day trading, a decline of 48% from the average session volume of 16,965,762 shares. The stock had previously closed at $0.14.

Analyst Upgrades and Downgrades

Separately, Noble Financial raised Zomedica to a “strong-buy” rating in a research note on Monday, November 11th.

Zomedica Price Performance

The stock has a market capitalization of $135.43 million, a PE ratio of -2.30 and a beta of 1.04.

Hedge Funds Weigh In On Zomedica

A hedge fund recently raised its stake in Zomedica stock. Geode Capital Management LLC increased its holdings in shares of Zomedica Corp. (NYSEAMERICAN:ZOM) by 3.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 9,929,716 shares of the company’s stock after buying an additional 321,395 shares during the quarter. Geode Capital Management LLC owned 1.01% of Zomedica worth $1,363,000 as of its most recent SEC filing. Institutional investors and hedge funds own 8.95% of the company’s stock.

About Zomedica

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.